Autolus Therapeutics plc Inventory Write-down
Autolus Therapeutics plc (AUTL) reported Inventory Write-down of $1.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-08-11
- Autolus Therapeutics plc inventory write-down for the quarter ending 2026-06-30 was $1.20M, a 52.00% decline year-over-year.
- Autolus Therapeutics plc inventory write-down for the quarter ending 2026-03-31 was $2.05M.
- Autolus Therapeutics plc inventory write-down for the quarter ending 2025-12-31 was $4.70M.
- Autolus Therapeutics plc inventory write-down for the quarter ending 2025-09-30 was $4.30M.
- Autolus Therapeutics plc inventory write-down for fiscal 2025 was $12.28M.
- Autolus Therapeutics plc inventory write-down for fiscal 2024 was $0.00.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.20M 10-Q · filed 2026-08-11 | $3.10M 10-Q · filed 2026-08-11 | $7.95M derived: sum of 3 quarters · filed 2026-08-11 | $12.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.05M 10-Q · filed 2026-05-14 | $6.75M derived: sum of 2 quarters · filed 2026-05-14 | $11.05M derived: sum of 3 quarters · filed 2026-05-14 | $13.55M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $9.00M derived: sum of 2 quarters · filed 2026-03-27 | $11.50M derived: sum of 3 quarters · filed 2026-08-11 | $12.28M 10-K · filed 2026-03-27 |
| 2025-09-30 | $4.30M 10-Q · filed 2025-11-12 | $6.80M derived: sum of 2 quarters · filed 2026-08-11 | $7.58M 10-Q · filed 2025-11-12 | $6.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.50M 10-Q · filed 2026-08-11 | $3.24M 10-Q · filed 2026-08-11 | $2.50M derived: sum of 3 quarters · filed 2026-08-11 | $2.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | $0.00 derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | $0.00 derived: sum of 3 quarters · filed 2026-03-27 | $0.00 10-K · filed 2026-03-27 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |